ABVC BioPharma, Inc. Provision for Other Credit Losses
ABVC BioPharma, Inc. (ABVC) reported Provision for Other Credit Losses of $616.45 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForOtherCreditLosses · last filed 2026-08-12
- ABVC BioPharma, Inc. provision for other credit losses for the quarter ending 2026-06-30 was $5.00.
- ABVC BioPharma, Inc. provision for other credit losses for the quarter ending 2026-03-31 was $616.45K, a 5040.06% increase year-over-year.
- ABVC BioPharma, Inc. provision for other credit losses for the quarter ending 2025-12-31 was $602.48K.
- ABVC BioPharma, Inc. provision for other credit losses for the quarter ending 2025-09-30 was $0.00.
| Period end | Provision for Other Credit Losses 3 month | Provision for Other Credit Losses 6 month | Provision for Other Credit Losses 9 month | Provision for Other Credit Losses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $616.45K 10-Q · filed 2026-08-12 | $1.22M derived: sum of 3 quarters · filed 2026-08-12 | $1.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $616.45K 10-Q · filed 2026-05-18 | $1.22M derived: sum of 2 quarters · filed 2026-08-12 | $1.22M derived: sum of 3 quarters · filed 2026-08-12 | $1.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $602.48K derived: 10-Q 12 month − 10-Q/A 9 month · filed 2026-08-12 | $602.48K derived: sum of 2 quarters · filed 2026-08-12 | $602.48K derived: sum of 3 quarters · filed 2026-08-12 | $614.47K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $11.99K 10-Q/A · filed 2026-03-03 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $11.99K 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $11.99K 10-Q · filed 2025-04-30 | |||
| 2024-12-31 | $11.99K 10-Q/A · filed 2026-03-03 |